LUNAM Université, Angers, France.
Service de Néphrologie-Dialyse-Transplantation, CHU Angers, Angers, France.
PLoS One. 2018 Apr 25;13(4):e0196101. doi: 10.1371/journal.pone.0196101. eCollection 2018.
IgA nephropathy (IgAN), the most frequent primary glomerulonephritis, affects young patients and is associated with a high risk of progression to end-stage renal disease. Consequently, patients with IgAN constitute an important proportion of candidates for kidney transplantation. Several studies showed a significant risk of IgAN recurrence on kidney graft, but the risks factors for recurrence remain to be accurately evaluated. Indeed, early identification of at risk patients may allow the optimization of treatment and the reduction of recurrence rate on the graft. In the present work, we studied the relationship between post-transplant serum IgA (sIgA) levels and the risk of IgAN recurrence after kidney transplantation. Recipients with IgAN had higher levels of sIgA as compared to patients with other nephropathies (p<0.05). The prevalence of IgAN recurrence was 20.8% during the period of analysis (mean follow-up of 6 ± 3.2 years). Serum IgA levels at M6, M12 and M24 post-transplant were significantly higher in patients with IgAN recurrence as compared to those without (p = 0.009, p = 0.035 and p = 0.029, respectively). Using receiver operating curve (ROC), sIgA at M6 and M12 post-transplant were significantly associated with IgAN recurrence (AUC = 0.771, p = 0.004 and AUC = 0.767, p = 0.016, respectively), while serum creatinine and proteinuria were not. Serum IgA level at month 6 was significantly associated with the occurrence of post-transplant IgA recurrence, whether it was analyzed as a continuous or a categorical variable. After successive adjustment on age, gender and proteinuria, sIgA remained a significant risk factor of post-transplant IgAN recurrence. Finally, survival free of IgAN recurrence was significantly better in patients with sIgA<222 mg/dL at month 6 as compare to IgAN patients with sIgA≥222 mg/dL (p = 0.03). Thus, the present work supports a link between post-transplant sIgA levels and IgAN recurrence and suggests that sIgA may be a valuable predictive biomarker of IgAN recurrence in kidney transplant recipients.
IgA 肾病(IgAN)是最常见的原发性肾小球肾炎,影响年轻患者,并且与进展为终末期肾病的风险较高相关。因此,IgAN 患者构成了肾移植候选者的重要比例。几项研究表明,IgAN 在肾移植物中复发的风险显著,但复发的危险因素仍有待准确评估。事实上,早期识别高危患者可能允许优化治疗并降低移植物的复发率。在本研究中,我们研究了移植后血清 IgA(sIgA)水平与肾移植后 IgAN 复发风险之间的关系。与患有其他肾病的患者相比,患有 IgAN 的患者的 sIgA 水平更高(p<0.05)。在分析期间(平均随访 6±3.2 年),IgAN 复发的发生率为 20.8%。与无 IgAN 复发的患者相比,IgAN 复发患者在移植后 M6、M12 和 M24 时的血清 IgA 水平显着更高(p=0.009、p=0.035 和 p=0.029)。使用接收者操作特征曲线(ROC),移植后 M6 和 M12 时的 sIgA 与 IgAN 复发显着相关(AUC=0.771,p=0.004 和 AUC=0.767,p=0.016),而血清肌酐和蛋白尿则不然。血清 IgA 水平在第 6 个月时与移植后 IgA 复发的发生显着相关,无论是作为连续变量还是分类变量进行分析。在连续调整年龄、性别和蛋白尿后,sIgA 仍然是移植后 IgAN 复发的显著危险因素。最后,与 sIgA<222mg/dL 的 IgAN 患者相比,sIgA 在第 6 个月时<222mg/dL 的患者无 IgAN 复发的生存率显着更好(p=0.03)。因此,本研究支持移植后 sIgA 水平与 IgAN 复发之间的联系,并表明 sIgA 可能是肾移植受者 IgAN 复发的有价值的预测生物标志物。